

해외 바이오의약품 임상 현황 (2021.1.11~2021.1.17)

한국바이오의약품협회, 2021.1.19.  
출처: ClinicalTrials.gov

○ 미국 30건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04711811	Chronic Musculoskeletal Pain	Chronic Pain	Drug: HB-adMSC	Hope Biosciences Hope Biosciences Stem Cell Research Foundation	Phase 1	---
NCT04060407	CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)	Metastatic Melanoma	Drug: CD24Fc Drug: Ipilimumab Drug: Nivolumab	OncoImmune, Inc.   Huntsman Cancer Institute   National Cancer Institute (NCI)	Phase 1 Phase 2	---
NCT03735589	Specialized Immune Cells (mCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Stage II Fallopian Tube Cancer AJCC v8 Stage II Ovarian Cancer AJCC v8 Stage II Primary Peritoneal Cancer AJCC v8 Stage IIA Fallopian Tube Cancer AJCC v8 Stage IIA Ovarian Cancer AJCC v8 Stage IIA Primary Peritoneal Cancer AJCC v8 Stage IIB Fallopian Tube Cancer AJCC v8 Stage IIB Ovarian Cancer AJCC v8 Stage IIB Primary Peritoneal Cancer AJCC v8 Stage III Fallopian Tube Cancer AJCC v8 Stage III Ovarian Cancer AJCC v8 Stage III Primary Peritoneal Cancer AJCC v8 Stage IIIA Fallopian Tube Cancer AJCC v8 Stage IIIA Ovarian Cancer AJCC v8 Stage IIIA Primary Peritoneal Cancer AJCC v8 Stage IIIA1 Fallopian Tube Cancer AJCC v8 Stage IIIA1 Ovarian Cancer AJCC v8 Stage IIIA2 Fallopian Tube Cancer AJCC v8 Stage IIIA2 Ovarian Cancer AJCC v8 Stage IIIB Fallopian Tube Cancer AJCC v8 Stage IIIB Ovarian Cancer AJCC v8 Stage IIIB Primary Peritoneal Cancer AJCC v8 Stage IIIB Fallopian Tube Cancer AJCC v8 Stage IIIB Ovarian Cancer AJCC v8 Stage IIIC Ovarian Cancer AJCC v8 Stage IIIC Primary Peritoneal Cancer AJCC v8 Stage IVC Fallopian Tube Cancer AJCC v8 Stage IVC Ovarian Cancer AJCC v8 Stage IVC Primary Peritoneal Cancer AJCC v8 Stage IVA Fallopian Tube Cancer AJCC v8 Stage IVA Ovarian Cancer AJCC v8 Stage IVA Primary Peritoneal Cancer AJCC v8 Stage IVB Fallopian Tube Cancer AJCC v8 Stage IVB Ovarian Cancer AJCC v8 Stage IVB Primary Peritoneal Cancer AJCC v8	Biological: Alpha-type-1 Polarized Dendritic Cells Biological: Autologous Natural Killer Cell-like CTLs	Roswell Park Cancer Institute   National Cancer Institute (NCI)	Phase 1 Phase 2	---
NCT04700163	RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers	Covid19	Biological: C144-LS and C-135-LS	Rockefeller University	Phase 1	---
NCT04680468	Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma	Myeloma	Drug: Belantamab mafodotin	Abramson Cancer Center of the University of Pennsylvania   GlaxoSmithKline	Phase 2	---
NCT04664738	PEP on a Skin Graft Donor Site Wound	Skin Graft	Biological: 10% PEP Drug: TISSEEL Biological: 20% PEP	Steven L. Moran   Mayo Clinic	Phase 1	---
NCT04660201	Anthrax AV7909 Liquid vs Lyophilized	Anthrax Anthrax Immunisation	Biological: AV7909	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	---
NCT04649359	Study of PF-06863135 Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb	Multiple Myeloma	Drug: PF-06863135	Pfizer	Phase 2	---
NCT04626583	Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells	Mesenchymal Stromal Cells Cornea Safety Corneal Defect	Biological: Allogeneic MSC	University of Illinois at Chicago   United States Department of Defense	Phase 1	---
NCT04605614	64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression	Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm	Radiation: Copper Cu 64-DOTA-pembrolizumab Biological: Pembrolizumab Procedure: Positron Emission Tomography	City of Hope Medical Center   National Cancer Institute (NCI)	Phase 1	---
NCT04590872	An Immunotherapy Vaccine (P1pepToDC) for the Treatment of Patients With Type 1 Diabetes	Type 1 Diabetes Mellitus	Biological: Tolerogenic Dendritic Cell Vaccine	City of Hope Medical Center	Phase 1	---
NCT04588038	NT-17 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery	Recurrent Head and Neck Squamous Cell Carcinoma Recurrent Hypopharyngeal Squamous Cell Carcinoma Recurrent Laryngeal Squamous Cell Carcinoma Recurrent Oral Cavity Squamous Cell Carcinoma Recurrent Oropharyngeal Squamous Cell Carcinoma Resectable Oropharyngeal Squamous Cell Carcinoma	Biological: Efinetakin alfa	Hyunseok Kang, MD   NeolmmuneTech   University of California, San Francisco	Phase 1	---
NCT04561206	Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed Classical Hodgkin Lymphoma	Recurrent Classic Hodgkin Lymphoma	Drug: Brentuximab Vedotin Biological: Nivolumab	City of Hope Medical Center   National Cancer Institute (NCI)	Phase 2	---
NCT04510051	CAR T Cells After Lymphodepletion for the Treatment of IL13Ra2 Positive Recurrent or Refractory Brain Tumors in Children	Malignant Brain Neoplasm Recurrent Malignant Brain Neoplasm Refractory Malignant Brain Neoplasm	Drug: Cyclophosphamide Drug: Fludarabine Biological: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes	City of Hope Medical Center   National Cancer Institute (NCI)	Phase 1	---
NCT04484012	Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Recurrent Mantle Cell Lymphoma Refractory Mantle Cell Lymphoma	Drug: Acalabrutinib Biological: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes	City of Hope Medical Center   National Cancer Institute (NCI)	Phase 2	---
NCT04177004	Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant	Allogeneic Hematopoietic Stem Cell Transplant Recipient Hematopoietic and Lymphoid Cell Neoplasm	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Cyclophosphamide Drug: Etoposide Radiation: Fractionated Stereotactic Radiation Therapy Drug: Goat Milk Biological: Palifermin Drug: Sirolimus Drug: Tacrolimus	City of Hope Medical Center   National Cancer Institute (NCI)	Phase 1	---
NCT04174560	Phase I Norovirus Challenge Model	Gastroenteritis Norovirus	Biological: Norovirus GII.4 Challenge Pool	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	---
NCT04150042	A Study of Melphalan, BCNU, Vitamin B12b, Vitamin C, and Stem Cell Infusion in People With Pancreatic Cancer	Pancreatic Adenocarcinoma Metastatic BRCA1 Mutation BRCA2 Mutation	Drug: Melphalan Drug: BCNU Drug: Vitamin B12B Drug: Vitamin C Drug: Ethanol Device: Autologous Hematopoietic Stem Cells	General Oncology, Inc.	Phase 1	---
NCT04119830	Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer	Metastatic Colorectal Adenocarcinoma Microsatellite Stable Mismatch Repair Proficient Refractory Colorectal Adenocarcinoma Stage III Colorectal Cancer AJCC v8 Stage IIIA Colorectal Cancer AJCC v8 Stage IIIB Colorectal Cancer AJCC v8 Stage IIIC Colorectal Cancer AJCC v8 Stage IVD Colorectal Cancer AJCC v8 Stage IVE Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8 Unresectable Colorectal Adenocarcinoma	Biological: Pembrolizumab Other: Questionnaire Administration Drug: Rintatolimod	Roswell Park Cancer Institute   National Cancer Institute (NCI)   AIM BioPharma	Phase 2	---
NCT04282044	Study of CRX100 in Patients With Advanced Solid Tumors	Solid Tumor, Adult Triple Negative Breast Cancer Colorectal Cancer Hepatocellular Carcinoma Osteosarcoma Epithelial Ovarian Cancer Gastric Cancer	Biological: CRX100 suspension for infusion	BioEclipse Therapeutics	Phase 1	---
NCT04695847	M1231 in Participants With Solid Tumors	Metastatic Solid Tumors Esophageal Cancer Non-Small Cell Lung Cancer	Drug: M1231	EMD Serono Research & Development Institute, Inc.   Merck KGaA, Darmstadt, Germany   EMD Serono	Phase 1	---
NCT04626791	Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma	Mantle Cell Lymphoma	Drug: Acalabrutinib Drug: Bortezomib Drug: Cyclophosphamide Drug: Cytarabine Drug: Doxorubicin Hydrochloride Drug: Prednisone Biological: Rituximab Biological: Rituximab and Hyaluronidase Human	Academic and Community Cancer Research United   National Cancer Institute (NCI)	Phase 2	---
NCT04581785	Gene Therapy With hLB-001 in Pediatric Patients With Severe Methylmalonic Acidemia	Methylmalonic Acidemia	Biological: hLB-001	LogicBio Therapeutics, Inc.	Phase 1 Phase 2	---
NCT04167618	177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma	Medulloblastoma, Childhood	Drug: 177Lu-DTPA-omburtamab	Y-mAbs Therapeutics	Phase 1 Phase 2	---
NCT04707469	Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes	Diabetes Mellitus, Type 2	Drug: Oral semaglutide	Novo Nordisk A/S	Phase 3	---
NCT04677179	A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: LY3471851 Drug: Placebo	Eli Lilly and Company	Phase 2	---
NCT04660539	A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis Optica Spectrum Disorder	Drug: satralizumab Drug: azathioprine (AZA) Drug: mycophenolate mofetil (MMF) Drug: oral corticosteroids	Hoffmann-La Roche	Phase 3	---
NCT04704843	A Study of JNJ-64304500 or Guselkumab in Adult Participants With Celiac Disease	Celiac Disease	Drug: JNJ-64304500 Drug: Guselkumab Drug: JNJ-64304500-Placebo Drug: Guselkumab-Placebo	Janssen Research & Development, LLC	Phase 1	---
NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-cell Lymphoma	Drug: Obinutuzumab Drug: Glofitamab Drug: Rituximab Drug: Tocilizumab Drug: Gemcitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 3	---
NCT03770299	An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease	Non-Small Cell Lung Cancer Non-Small-Cell Lung Carcinoma Circulating Tumor DNA	Biological: Nivolumab Drug: Vinorelbine Drug: Gemcitabine Drug: Docetaxel Drug: Pemetrexed Drug: Cisplatin Drug: Carboplatin Drug: Paclitaxel Other: Observation	Bristol-Myers Squibb	Phase 2	---

해외 바이오의약품 임상 현황 (2021.1.11~2021.1.17)

한국바이오의약품협회, 2021.1.19.  
출처: ClinicalTrials.gov

○ 영국 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04630028	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: Ustekinumab Dose Based on BSA and Body Weight Drug: Matching Placebo	Janssen Research & Development, LLC	Phase 3	---
NCT04619420	A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease	Alzheimer Disease Cognitive Dysfunction Dementia	Drug: JNJ-63733657 Drug: Placebo	Janssen Research & Development, LLC	Phase 2	---
NCT04655807	A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease	Crohn Disease	Drug: JNJ-64304500 Drug: Placebo Drug: Adalimumab Drug: Ustekinumab	Janssen Research & Development, LLC	Phase 2	---
NCT04634552	A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma	Hematological Malignancies	Drug: Talquetamab	Janssen Research & Development, LLC	Phase 2	---
NCT04521231	A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients	B Cell Precursor Acute Lymphoblastic Leukemia	Drug: Blinatumomab	Amgen	Phase 1	---
NCT04684654	BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome	Healthy Participants Primary Sjögren's Syndrome	Biological: BMS-986325 Other: Placebo	Bristol-Myers Squibb	Phase 1	---

○ 프랑스 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04527380	A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis	Juvenile Psoriatic Arthritis Enthesitis Related Arthritis	Drug: Ixekizumab Drug: Adalimumab	Eli Lilly and Company	Phase 3	---
NCT04677179	A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: LY3471851 Drug: Placebo	Eli Lilly and Company	Phase 2	---

○ 독일 7건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04674826	A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjects	Healthy	Drug: Tralokinumab administered as 1 x X mL with Device A Device: Tralokinumab administered as 2 x Y mL with Device B	LEO Pharma	Phase 1	---
NCT04707469	Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes	Diabetes Mellitus, Type 2	Drug: Oral semaglutide	Novo Nordisk A/S	Phase 3	---
NCT04527380	A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis	Juvenile Psoriatic Arthritis Enthesitis Related Arthritis	Drug: Ixekizumab Drug: Adalimumab	Eli Lilly and Company	Phase 3	---
NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-cell Lymphoma	Drug: Obinituzumab Drug: Glofitamab Drug: Rituximab Drug: Tocilizumab Drug: Gemcitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 3	---
NCT04677179	A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: LY3471851 Drug: Placebo	Eli Lilly and Company	Phase 2	---
NCT03770299	An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease	Non-Small Cell Lung Cancer Non-Small-Cell Lung Carcinoma Circulating Tumor DNA	Biological: Nivolumab Drug: Vinorelbine Drug: Gemcitabine Drug: Docetaxel Drug: Pemetrexed Drug: Cisplatin Drug: Carboplatin Drug: Paclitaxel Other: Observation	Bristol-Myers Squibb	Phase 2	---
NCT04660539	A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis Optica Spectrum Disorder	Drug: satralizumab Drug: azathioprine (AZA) Drug: mycophenolate mofetil (MMF) Drug: oral corticosteroids	Hoffmann-La Roche	Phase 3	---

○ 중국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04660799	A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)	Lymphoma, Large B-Cell, Diffuse	Drug: Rituximab IV Drug: Rituximab SC Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Drug: Paracetamol Drug: Diphenhydramine hydrochloride or alternative antihistamine	Hoffmann-La Roche	Phase 2	---
NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-cell Lymphoma	Drug: Obinituzumab Drug: Glofitamab Drug: Rituximab Drug: Tocilizumab Drug: Gemcitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 3	---

○ 일본 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04678882	Dupilumab in Japanese Patients With Atopic Dermatitis	Atopic Dermatitis	Drug: Placebo Drug: Dupilumab SAR231893	Sanofi Regeneron Pharmaceuticals	Phase 3	---
NCT04677179	A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: LY3471851 Drug: Placebo	Eli Lilly and Company	Phase 2	---
NCT04660539	A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis Optica Spectrum Disorder	Drug: satralizumab Drug: azathioprine (AZA) Drug: mycophenolate mofetil (MMF) Drug: oral corticosteroids	Hoffmann-La Roche	Phase 3	---